Phase
Startup
Xinnate
Xinnate AB develops proprietary peptides for prevention and treatment of wound and topical applications. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations.
Did you know?
The body’s natural defence to promote healing is the secret in Xinnate´s gel.
Non-invasive cardiac pressure monitoring device
Amplify the efficacy of pharmaceutical treatments
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
A "check-in buddy" for the elderly
Cell factories for dairy processing
Implants of magnesium alloys
Digital service for patients
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
Medical device that reduces pain during vein operation
Neonatal Lung Analyzer
Prebiotics for irritable bowel syndrome
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Nanotechnology based infection control
Bio-based vegan coating for fruits and vegetables
Short chain fatty acids can be delivered to the colon
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Converting waste flows into valuable raw materials
Gene editing analysis solution
Stroke detection device
An innovative digital medical service for men over 40
Safer medical needles for prostate biopsy
Wound treatment gel
